Argent Biopharma Ltd Total Liabilities
Argent Biopharma Ltd total liabilities. Based on the latest financial reports, Argent Biopharma Ltd (RGT) has total liabilities worth AU$11.10 Million AUD (≈ $7.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RGT asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Argent Biopharma Ltd (2006–2025)
Total liabilities of Argent Biopharma Ltd from 2006 to 2025. This chart illustrates how Argent Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Argent Biopharma Ltd (RGT) long-term investment share to see how much of total assets are deployed in long-term investments.
Argent Biopharma Ltd Competitors by Total Liabilities
The table below lists competitors of Argent Biopharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fintech Select Ltd
V:FTEC
|
Canada | CA$1.19 Million |
|
Panther Metals Ltd
AU:PNT
|
Australia | AU$137.29K |
|
CPD SA
WAR:CPD
|
Poland | zł970.00K |
|
MOBA Network publ AB
ST:MOBA
|
Sweden | Skr357.78 Million |
|
MW Trade S.A.
WAR:MWT
|
Poland | zł3.94 Million |
|
Northern 2 Vct Plc
LSE:NTV
|
UK | GBX207.00K |
|
Arctic Star Exploration Corp
V:ADD
|
Canada | CA$1.56 Million |
|
Vintage Energy Ltd
AU:VEN
|
Australia | AU$22.98 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Argent Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RGT total asset value.
Liquidity & Leverage Metrics
Argent Biopharma Ltd Total Liabilities Ratios Explained
Argent Biopharma Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argent Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argent Biopharma Ltd (2006–2025)
The table below shows the annual total liabilities of Argent Biopharma Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$11.10 Million ≈ $7.85 Million |
-33.20% |
| 2024-06-30 | AU$16.61 Million ≈ $11.75 Million |
-7.79% |
| 2023-06-30 | AU$18.02 Million ≈ $12.75 Million |
+34.66% |
| 2022-06-30 | AU$13.38 Million ≈ $9.47 Million |
+28.51% |
| 2021-06-30 | AU$10.41 Million ≈ $7.37 Million |
+115.31% |
| 2020-06-30 | AU$4.83 Million ≈ $3.42 Million |
+119.90% |
| 2019-06-30 | AU$2.20 Million ≈ $1.56 Million |
-69.90% |
| 2018-06-30 | AU$7.30 Million ≈ $5.17 Million |
+45.16% |
| 2017-06-30 | AU$5.03 Million ≈ $3.56 Million |
+8.62% |
| 2016-06-30 | AU$4.63 Million ≈ $3.28 Million |
+680.07% |
| 2015-06-30 | AU$593.79K ≈ $420.14K |
+38.32% |
| 2014-06-30 | AU$429.29K ≈ $303.75K |
-43.44% |
| 2013-06-30 | AU$758.99K ≈ $537.03K |
+270.35% |
| 2012-06-30 | AU$204.94K ≈ $145.01K |
-34.31% |
| 2012-04-30 | AU$312.00K ≈ $220.76K |
+17.50% |
| 2011-06-30 | AU$265.52K ≈ $187.87K |
-98.46% |
| 2010-06-30 | AU$17.27 Million ≈ $12.22 Million |
+5.12% |
| 2009-06-30 | AU$16.43 Million ≈ $11.62 Million |
+2233.90% |
| 2008-06-30 | AU$703.90K ≈ $498.06K |
-27.97% |
| 2007-06-30 | AU$977.20K ≈ $691.43K |
-62.53% |
| 2006-06-30 | AU$2.61 Million ≈ $1.85 Million |
-- |
About Argent Biopharma Ltd
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more